{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:24:14Z","timestamp":1773923054360,"version":"3.50.1"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bulcan.2019.03.013","type":"journal-article","created":{"date-parts":[[2019,5,11]],"date-time":"2019-05-11T23:22:17Z","timestamp":1557616937000},"page":"550-559","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Caract\u00e9ristiques pr\u00e9th\u00e9rapeutiques et \u00e9volutives des patients atteints de la leuc\u00e9mie my\u00e9lo\u00efde chronique \u00e0 Abidjan C\u00f4te d\u2019Ivoire"],"prefix":"10.1016","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1770-1172","authenticated-orcid":false,"given":"Dohoma Alexis","family":"Silu\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2113-568X","authenticated-orcid":false,"given":"Boidy","family":"Kouakou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clotaire Danho","family":"Nanho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismael","family":"Kamara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stella","family":"Djoko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takam","family":"Sowhe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u2019Dogomo","family":"Meit\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romeo","family":"Ayemou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N\u2019Dhatz","family":"Emeuraude","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aissata","family":"Tolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gustave","family":"Koffi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahima","family":"Sanogo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1 Suppl. 1","key":"10.1016\/j.bulcan.2019.03.013_bib0130","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.seminhematol.2006.12.001","article-title":"Introduction: chronic myelogenous leukemia (CML)","volume":"44","author":"Jabbour","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining","volume":"43","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.bulcan.2019.03.013_bib0140","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1182\/blood-2008-03-144790","article-title":"Molecular biology of bcr-abl1-positive chronic myeloid leukemia","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0145","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1002\/(SICI)1097-0142(19991215)86:12<2632::AID-CNCR7>3.0.CO;2-A","article-title":"Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients","volume":"86","author":"Sacchi","year":"1999","journal-title":"Cancer"},{"issue":"Suppl. 2","key":"10.1016\/j.bulcan.2019.03.013_bib0150","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"issue":"22","key":"10.1016\/j.bulcan.2019.03.013_bib0155","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.bulcan.2019.03.013_bib0160","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0165","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0170","unstructured":"Deepak C, Firoz A, Priya I, et al. Cytogentic investigation in chronic myeloid leukemia: study from an Indian population. Asian Pacific J Cancer Prev 2006;7:423\u20136."},{"key":"10.1016\/j.bulcan.2019.03.013_bib0175","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1002\/1097-0142(19801115)46:10<2221::AID-CNCR2820461019>3.0.CO;2-8","article-title":"Chromosomes and causation of human cancer and leukemia: XL. The Ph1 and other translocation in CML","volume":"46","author":"Sandberg","year":"1980","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.bulcan.2019.03.013_bib0180","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S1658-3876(08)50025-2","article-title":"Additional chromosomal abnormalities in Philadelphia-positive chronic myeloid leukemia","volume":"1","author":"Naz Syed","year":"2008","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"22","key":"10.1016\/j.bulcan.2019.03.013_bib0185","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1182\/blood.V128.22.1926.1926","article-title":"Impact of additional chromosomal abnormalities in Philadelphia-positive clone on prognosis of CML patients treated with tyrosine kinase inhibitors","volume":"128","author":"Bingcheng","year":"2016","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2019.03.013_bib0190","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1182\/blood-2011-10-384651","article-title":"Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis","volume":"120","author":"Luatti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0195","series-title":"\u00c9tude des facteurs pronostiques de la leuc\u00e9mie my\u00e9lo\u00efde chronique en phase chronique chez le noir Africain au CHU de Yopougon","first-page":"3045","author":"Dongho","year":"2002"},{"issue":"4","key":"10.1016\/j.bulcan.2019.03.013_bib0200","article-title":"\u00c9pid\u00e9miologie actuelle des h\u00e9mopathies malignes dans les services d\u2019h\u00e9matologie oncologie m\u00e9dicale et de m\u00e9decine interne de l\u2019h\u00f4pital du Point G, Bamako","volume":"XX","author":"Diallo","year":"2005","journal-title":"Mali Med"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0205","first-page":"22123","article-title":"Chronic myeloid leukemia: model or exception","volume":"2","author":"Chapuis","year":"2002","journal-title":"Med J Switzerland"},{"issue":"35","key":"10.1016\/j.bulcan.2019.03.013_bib0210","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bulcan.2019.03.013_bib0215","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.bulcan.2019.03.013_bib0220","first-page":"1333","article-title":"The effect of imatinib mesylate on patients with Philadelphia chromosome-positive chronic myeloid leukemia with secondary chromosomal aberrations","volume":"9","author":"Mohamed Anwar","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0225","doi-asserted-by":"crossref","unstructured":"Koffi KG, Nanho D, N\u2019dathz E. The effect of imatinib mesylate for newly diagnosed philadephia chromosome-positive chronic phase myeloid leukemia. Advances Hematol 2010;2010:268921.","DOI":"10.1155\/2010\/268921"},{"issue":"26","key":"10.1016\/j.bulcan.2019.03.013_bib0230","doi-asserted-by":"crossref","first-page":"6760","DOI":"10.1182\/blood-2011-08-373902","article-title":"Impact of additional cytogenetic aberrations at diagnosis on progression of CML: long-term observation of 1151 patients from randomized CML Study IV","volume":"118","author":"Fabarius","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.bulcan.2019.03.013_bib0235","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bulcan.2019.03.013_bib0240","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2002-03-0777","article-title":"The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML","volume":"100","author":"O\u2019Dwyer","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.bulcan.2019.03.013_bib0245","first-page":"502","article-title":"The impact of additional cytogenetic abnormalities at diagnosis and during therapy with tyrosine kinase inhibitors in chronic myeloid leukaemia","volume":"8","author":"Crisan","year":"2015","journal-title":"J Med Life"},{"issue":"12","key":"10.1016\/j.bulcan.2019.03.013_bib0125","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511930178X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745511930178X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,24]],"date-time":"2019-11-24T22:43:03Z","timestamp":1574635383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745511930178X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S000745511930178X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.03.013","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Caract\u00e9ristiques pr\u00e9th\u00e9rapeutiques et \u00e9volutives des patients atteints de la leuc\u00e9mie my\u00e9lo\u00efde chronique \u00e0 Abidjan C\u00f4te d\u2019Ivoire","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2019.03.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}